Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 9/20 | 0.44 |
| ▸ | TAS1R1 | Q7RTX1 | 9/20 | 0.44 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.39 |
| ▸ | CENPE | Q02224 | 2/20 | 0.39 |
| ▸ | THRA | P10827 | 1/20 | 0.38 |
| ▸ | THRB | P10828 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3233445 | 0.87 | CENPE (0.52) | TAS1R3TAS1R1CSNK2A1PPARGRAB9A | |
| SCHEMBL2617236 | 0.86 | TAS1R3 (0.53) | TAS1R3TAS1R1CSNK2A1PPARGRAB9A | |
| SCHEMBL4774274 | 0.86 | TAS1R3 (0.44) | TAS1R3TAS1R1RAB9ACENPETHRB | |
| SCHEMBL2630562 | 0.85 | MAPT (0.47) | TAS1R3TAS1R1CSNK2A1RAB9ACENPE | |
| SCHEMBL3217194 | 0.83 | L3MBTL1 (0.39) | TAS1R3TAS1R1PPARGRAB9ACENPE | |
| SCHEMBL10214857 | 0.82 | F10 (0.41) | TAS1R3TAS1R1PPARGCENPEPOLB | |
| SCHEMBL4769873 | 0.82 | SCD (0.45) | PPARGRAB9ATHRBPOLBMEN1 | |
| SCHEMBL13644428 | 0.82 | TAS1R3 (0.41) | TAS1R3TAS1R1RAB9ACENPETHRB | |
| SCHEMBL13183917 | 0.81 | TAS1R3 (0.41) | TAS1R3TAS1R1PPARGRAB9ANCOA3 | |
| SCHEMBL13456978 | 0.79 | TAS1R3 (0.46) | TAS1R3TAS1R1CSNK2A1PPARGRAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | claimed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | claimed |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2006-11-02 | — | — | US | claimed |
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | CYTOKINETICS, INC. | 2010-03-18 | — | — | US | disclosed |
| US-7582668-B2 | Imidazoyl-benzamide anti-cancer agents | CYTOKINETICS, INCORPORATED (US) | 2009-09-01 | — | — | US | disclosed |
| US-7504413-B2 | N-(4-(imidazo[1,2A]pyridin-YL)phenethyl)benzamide inhibitors of the mitotic kinesin CENP-E for treating certain cellular proliferation diseases | CYTOKINETICS, INC. (US) | 2009-03-17 | — | — | US | disclosed |
| EP-1951719-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | CYTOKINETICS, INCORPORATED | 2007-06-28 | — | — | US | disclosed |
| WO-2007056469-A2 | CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069453-A1 | Certain Chemical Entities, Compositions, and Methods | KIF5B, KIF2C, PLK1 | TAS1R3 4827/4885TAS1R1 4847/4885CSNK2A1 401/4885 |
| US-20060247289-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | TAS1R3 4827/4885TAS1R1 4847/4885CSNK2A1 401/4885 |
| US-20070149516-A1 | Certain chemical entities, compositions, and methods | KIF5B, KIF2C, PLK1 | TAS1R3 4827/4885TAS1R1 4847/4885CSNK2A1 401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.